These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 3090218)

  • 21. Chagas' disease and the autoimmunity hypothesis.
    Kierszenbaum F
    Clin Microbiol Rev; 1999 Apr; 12(2):210-23. PubMed ID: 10194457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro cellular immunity in Chagas' disease.
    Toledo Barros MA; Amato Neto V; Mendes E; Mota I
    Clin Exp Immunol; 1979 Nov; 38(2):376-80. PubMed ID: 118840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Exoantigens of Trypanosoma cruzi. Epitopes reactive against immunoglobulins of patients with Chagas' disease].
    Gruppi A; Moretti ER; Basso B; Vottero-Cima E
    Medicina (B Aires); 1988; 48(2):161-6. PubMed ID: 3148093
    [No Abstract]   [Full Text] [Related]  

  • 24. Trypanosoma cruzi: the immunological consequences of infection.
    Hudson L
    J Cell Biochem; 1983; 21(4):299-304. PubMed ID: 6418751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of tests based on Trypanosoma cruzi excreted-secreted antigens in an endemic area for Chagas' disease in Bolivia.
    Zarate-Blades CR; Bladés N; Nascimento MS; da Silveira JF; Umezawa ES
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):229-32. PubMed ID: 17020793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infection, mimics, and autoimmune disease.
    Rose NR
    J Clin Invest; 2001 Apr; 107(8):943-4. PubMed ID: 11306595
    [No Abstract]   [Full Text] [Related]  

  • 27. EVI antibodies in patients with Chagas' disease: relationship with anti-Trypanosoma cruzi immunoglobulins and effects of specific treatment.
    Brener Z; Ramirez LE; Krettli AU; Cançado JR
    Mem Inst Oswaldo Cruz; 1983; 78(4):437-42. PubMed ID: 6443630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease.
    Zhang L; Tarleton RL
    J Infect Dis; 1999 Aug; 180(2):480-6. PubMed ID: 10395865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of antigens of culture forms of Trypanosoma cruzi and Trypanosoma rangeli recognized by sera from patients with chronic Chagas' disease.
    Grögl M; Kuhn RE
    J Parasitol; 1984 Oct; 70(5):822-4. PubMed ID: 6439848
    [No Abstract]   [Full Text] [Related]  

  • 30. Specific immunodiagnosis of Chagas disease: immunodiffusion test using a specific serum anti-Trypanosoma cruzi component 5.
    Breniere FS; Carlier Y; Carrasco R; Molinedo S; Lemesre JL; Desjeux P; Afchain D
    Trop Geogr Med; 1987 Jul; 39(3):281-6. PubMed ID: 3124314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Circulating antigens of Trypanosoma cruzi in patients with Chagas' disease in an endemic area].
    Alonso JM; Pividori S; Guilleron C
    Medicina (B Aires); 1986; 46(1):69-72. PubMed ID: 3100908
    [No Abstract]   [Full Text] [Related]  

  • 32. Natural anti-Gal antibodies prevent, rather than cause, autoimmunity in human Chagas' disease.
    Gazzinelli RT
    Res Immunol; 1991 Feb; 142(2):164-7. PubMed ID: 1907755
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of antigens of Trypanosoma cruzi which induce antibodies during experimental Chagas' disease.
    Grögl M; Kuhn RE
    J Parasitol; 1985 Apr; 71(2):183-91. PubMed ID: 3923183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrophages in experimental Chagas' disease.
    Kuhn RE
    Immunol Ser; 1994; 60():495-502. PubMed ID: 8251589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of extracts rich in immune RNA on some immunopathological parameters of rats infected with Trypanosoma cruzi].
    Revelli S; Moreno H; Berra H; Velenti JL; Nocito A; Amerio N; Morini JC
    Bol Chil Parasitol; 1985; 40(3-4):51-7. PubMed ID: 3939407
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular basis of Trypanosoma cruzi and Leishmania interaction with their host(s): exploitation of immune and defense mechanisms by the parasite leading to persistence and chronicity, features reminiscent of immune system evasion strategies in cancer diseases.
    Ouaissi A; Ouaissi M
    Arch Immunol Ther Exp (Warsz); 2005; 53(2):102-14. PubMed ID: 15928579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chagas' disease: Trypanosoma cruzi vs. the host immune system. 36th forum in immunology.
    Res Immunol; 1991 Feb; 142(2):123-81. PubMed ID: 1907751
    [No Abstract]   [Full Text] [Related]  

  • 38. [Immunology of Chagas' disease].
    Abath FG
    Rev Bras Malariol Doencas Trop; 1983; 35():101-8. PubMed ID: 6438706
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunoprophylaxis against Chagas' disease.
    Teixeira AR
    Adv Exp Med Biol; 1977; 93():243-80. PubMed ID: 413341
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of Toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan.
    Pellegrini A; Guiñazu N; Giordanengo L; Cano RC; Gea S
    Future Microbiol; 2011 Dec; 6(12):1521-33. PubMed ID: 22122446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.